In terms of revenue, the global respiratory syncytial virus (RSV) therapeutics market was valued at US$ 923.4 Mn in 2018 and is anticipated to reach more than US$ 2200.0 Mn by 2026, expanding at a CAGR of 12.7% from 2019 to 2026.
The report analyzes and forecasts the respiratory syncytial virus (RSV) therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of respiratory syncytial virus (RSV) therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major respiratory syncytial virus (RSV) therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of respiratory syncytial virus (RSV) therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of respiratory syncytial virus (RSV) therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global respiratory syncytial virus (RSV) therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the respiratory syncytial virus (RSV) therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of respiratory syncytial virus (RSV) therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the respiratory syncytial virus (RSV) therapeutics market are include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd.
The global respiratory syncytial virus (RSV) therapeutics market has been segmented as follows:
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drugs Type
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary : Global Respiratory Syncytial Virus (RSV) Therapeutics Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis – Respiratory Syncytial Virus (RSV) Therapeutics Market
4.4. Epidemiology Assessment - Respiratory Syncytial Virus (RSV) Therapeutics Market
4.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, 2015-2026
4.5.1. Market Revenue Projection (US$ Mn)
4.5.2. Market Outlook
4.6. Key Trends
Chapter 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Drugs Type
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drugs Type, 2016–2026
5.3.1. Palivizumab
5.3.2. Ribavirin
5.3.3. Others
5.4. Market Attractiveness, by Drugs Type
Chapter 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Selection Technique
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast, by Dosage Form, 2016–2026
6.3.1. Oral
6.3.2. Injectable
6.3.3. Others
6.4. Market Attractiveness, by Dosage Form
Chapter 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast, by Distribution Channel, 2017–2026
7.3.1. Drug Stores & Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel
Chapter 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value and Volume Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
Chapter 9. North America Respiratory Syncytial Virus (RSV) Therapeutics Analysis and Forecast
9.1. Market Value Forecast, by Country , 2016–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Forecast, by Drugs Type, 2016–2026
9.3. Market Value Forecast, by Dosage Form, 2016–2026
9.4. Market Value Forecast, by Distribution Channel, 2016-2026
9.5. Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Drugs Type
9.5.3. By Dosage Form
9.5.4. By Distribution Channel
9.6. Key Trends
Chapter 10. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Forecast, by Drugs Type, 2016–2026
10.3. Market Value Forecast, by Dosage Form, 2016–2026
10.4. Market Value Forecast, by Distribution Channel, 2016-2026
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Drugs Type
10.5.3. By Dosage Form
10.5.4. By Distribution Channel
10.6. Key Trends
Chapter 11. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Forecast, by Drugs Type, 2016–2026
11.3. Market Value Forecast, by Dosage Form, 2016–2026
11.4. Market Value Forecast, by Distribution Channel, 2016-2026
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Drugs Type
11.5.3. By Dosage Form
11.5.4. By Distribution Channel
11.6. Key Trends
Chapter 12. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Forecast, by Drugs Type, 2016–2026
12.3. Market Value Forecast, by Dosage Form, 2016–2026
12.4. Market Value Forecast, by Distribution Channel, 2016-2026
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Drugs Type
12.5.3. By Dosage Form
12.5.4. By Distribution Channel
12.6. Key Trends
Chapter 13. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2026
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Forecast, by Drugs Type, 2016–2026
13.3. Market Value Forecast, by Dosage Form, 2016–2026
13.4. Market Value Forecast, by Distribution Channel, 2016-2026
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Drugs Type
13.5.3. By Dosage Form
13.5.4. By Distribution Channel
13.6. Key Trends
Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Merck & Co., Inc.
14.1.2. F. Hoffmann-La Roche Ltd.
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. AstraZeneca plc. (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Merck 7 Co., Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. AbbVie, Inc. (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Valeant Pharmaceuticals International, Inc. (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. GlaxoSmithKline plc. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. ReViral Ltd. (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Gilead Sciences, Inc. (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. MEDIVIR AB (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Teva Pharmaceuticals Industries Ltd. (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers